OSTARINE

Volume: 30 ML

Dosage: 10-20 MG/ML

Clinical dosing: 5 - 20 mg/day

Description:

Ostarine (also marked as MK-2866, Enobosarm and GTx-024) is a oral, nonsteroidal and Selective androgen receptor modulator (SARM), that was developed for treatment of conditions such as muscle wasting and osteoporosis (a health condition that weakens bones). In a phase 2a study, Ostarine was shown to increase lean body mass, decrease fat mass, and to modestly improve the homeostatic model assessment (HOMA), a measure of insulin sensitivity. It is the most and best clinically tested SARM to date. Ostarine has chemical formula C19H14F3N3O3, molecular mass 389.33 g.mol−1 and prolonged elimination half-life 24 hours. Ostarine was developed by GTx, Inc. for the treatment of conditions such as muscle wasting and osteoporosis. The company has invested approximately $ 35 million in its development. In August 2011, there was a double-blind, placebo controlled phase II trial that focused on elderly men and postmenopausal women. In this study Ostarine showed statistically significant improvements in total lean body mass and physical function without androgenic negative side effects (which usually occur with steroid therapy). In August 2013, GTx announced that Ostarine had failed in two Phase III clinical trials to treat wasting in people with lung cancer. They also said that is planned to pursue approval of Ostarine in Europe. In 2016, GTx began Phase II trials, to see if Ostarine might be effective to treat stress urinary incontinence in women, but these studies failed in 2018 to achieve their primary endpoint in the ASTRID test.

certification:

Compound Specifications:

Originale product made in UK.